Related Experiment Video
Updated: Feb 28, 2026
09:39
Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
Published on: February 13, 2018
10.1K
Drug therapy for chronic idiopathic axonal polyneuropathy
Janna Warendorf1, Alexander Fje Vrancken, Ivo N van Schaik
1Department of Neurology, Brain Center Rudolf Magnus, University Medical Center Utrecht, Heidelberglaan 100, Utrecht, Netherlands, 3584 CX.
The Cochrane Database of Systematic Reviews
|June 21, 2017
Summary
No drug treatments are proven effective for chronic idiopathic axonal polyneuropathy (CIAP). Further high-quality clinical trials are needed to establish effective therapies for this condition affecting older adults.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Chronic idiopathic axonal polyneuropathy (CIAP) is a progressive condition affecting the elderly, reducing quality of life.
- CIAP is diagnosed in 10-25% of individuals evaluated for polyneuropathy.
- An increasing prevalence in aging populations necessitates updated evidence on CIAP treatments.
Purpose of the Study:
- To evaluate the efficacy of drug therapies for CIAP in reducing disability and neurological symptoms.
- To assess the safety and adverse effects of drug treatments for CIAP.
Main Methods:
- Searched major databases (Cochrane, MEDLINE, Embase, Web of Science) and trials registries up to July 2016.
- Included randomized or quasi-randomized trials of drug therapy for CIAP in individuals aged 40+.
- Primary outcome was significant improvement in disability; secondary outcomes included symptom changes and adverse effects.
Main Results:
- 39 studies were identified and assessed for inclusion.
- All identified studies were excluded due to insufficient quality or relevance.
- Evidence from non-randomized studies was discussed.
Conclusions:
- No adequate randomized or quasi-randomized controlled clinical trials for CIAP drug therapy have been conducted.
- Currently, there is no proven efficacious drug therapy for chronic idiopathic axonal polyneuropathy.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:28Drug Therapy
327
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
327
01:27Peripheral Artery Disease III: Interprofessional Care
433
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
433
01:26Peripheral Artery Disease IV: Nursing Management
494
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
494
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604